 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 December 1994 | Volume 121 Issue 11 | Pages 873-876
Right-sided endocarditis caused by Staphylococcus aureus is a frequent complication of injection drug use. Fortunately, the prognosis for this infection when treated with the standard regimen of 4 to 6 weeks of parenteral antistaphylococcal antibiotics is favorable. Nevertheless, in many cases, once drug users feel better, they leave the hospital against medical advice before completing the full course of antibiotic therapy. This problem has stimulated interest in shortening the duration of antibiotic treatment by adding an aminoglycoside antibiotic to a penicillinase-resistant penicillin. Data from in vitro synergy studies and animal models of endocarditis suggest that S. aureus can be eradicated more quickly by combination therapy than by monotherapy. Reports of three prospective, nonrandomized clinical trials have been published that support the use of a 2-week course of a penicillinase-resistant penicillin and an aminoglycoside antibiotic to treat uncomplicated, exclusively right-sided endocarditis caused by methicillin-susceptible S. aureus in injection drug users.
Author and Article Information
From Cooper Hospital University Medical Center, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, Camden, New Jersey.
DIAGNOSIS AND TREATMENT
Short-Course Antibiotic Therapy for Right-sided Endocarditis Caused by Staphylococcus aureus in Injection Drug Users
Requests for Reprints: Mark DiNubile, MD, Division of Infectious Diseases, Room 274, Education and Research Building, 401 Haddon Avenue, Camden, New Jersey 08103.
Acknowledgments: The author thanks Dr. F. Javier Esteva Lorenzo for his scrutiny of the report published in Spanish (reference 20), Dr. Roseann Lorenick for her review of the manuscript, and Marie Rowland for her assistance in preparing the manuscript.
This article has been cited by other articles:
|
|
 |
|
  D. Yung, D. Kottachchi, B. Neupane, S. Haider, and M. Loeb Antimicrobials for right-sided endocarditis in intravenous drug users: a systematic review J. Antimicrob. Chemother., November 1, 2007; 60(5): 921 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Baddour, W. R. Wilson, A. S. Bayer, V. G. Fowler Jr, A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, et al. Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America Circulation, June 14, 2005; 111(23): e394 - e434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Moss and B. Munt Injection drug use and right sided endocarditis Heart, May 1, 2003; 89(5): 577 - 581. [Full Text] [PDF]
|
|
Article
